Mon, Apr 28, 10:04 AM (15 days ago)
**Akoya Biosciences, Inc. (AKYA) - Summary of 10-K/A Filing** **Company Overview:** Akoya Biosciences, Inc. (AKYA) filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The amendment includes Part III of the Form 10-K, which provides information on directors, executive officers, corporate governance, executive compensation, and other related matters. **Financial Performance:** The amendment does not modify or update the financial position, results of operations, cash flows, or other information contained in the Original Form 10-K. Therefore, the financial performance details are not provided in this summary. **Revenue and Net Income:** Not provided in this amendment. **Operating Expenses:** Not provided in this amendment. **Earnings Per Share:** Not provided in this amendment. **Strategic Overview:** The amendment focuses on corporate governance, executive compensation, and related party transactions. It does not provide a strategic overview or future outlook. **Future Outlook:** Not provided in this amendment. **Risk Factors:** Not provided in this amendment. **Financial Condition:** The amendment does not provide an update on the financial condition. **Market Position Changes:** Not provided in this amendment. **Corporate Governance:** The board of directors consists of seven members, five of whom are independent. The board is divided into three classes with staggered three-year terms. The amendment provides detailed information on the directors, their backgrounds, and committee memberships. **Executive Compensation:** The amendment includes a summary compensation table for the named executive officers, detailing their salaries, bonuses, stock awards, and other compensation for the fiscal years ended December 31, 2024 and 2023. It also describes the employment arrangements, severance plans, and other benefits provided to the executive officers. **Related Party Transactions:** The amendment discloses certain related party transactions, including agreements with stockholders, purchases from Argonaut Manufacturing, and indemnification agreements with directors and executive officers. **Director Independence:** The board of directors has determined that a majority of its members are independent, meeting the requirements of the Nasdaq Global Select Market and SEC rules. **Auditor Fees:** The amendment provides a summary of fees billed to the company by its independent public accounting firm, RSM US LLP, for the fiscal years ended December 31, 2024 and 2023. **Exhibits:** The amendment includes a list of exhibits filed, furnished, or incorporated by reference as part of the report. These exhibits include various agreements, plans, and policies related to the company's operations and governance. **Changes Made in Amendment:** The amendment primarily adds Part III of the Form 10-K, which was previously omitted from the Original Form 10-K. It does not modify or update the financial information or reflect events occurring after the filing of the Original Form 10-K.